Adrenocortical Carcinoma Metastasic in Adult on Complete Response with EDP-M and Local Therapy: A Single Case Report

#3029

Introduction: Adrenocortical carcinoma (ACC) in adults is a rare tumor (incidence 0.7-2/1000000/year). Median overall survival is 3-4 years and five-year survival is 0-28% in metastatic disease. The only curative therapy is complete surgical resection, plus adjuvant therapy depending on poor prognostic factors (ENSAT stage III, R1 resection or Ki67>10%). Both recurrent oligometastatic disease and patients who respond to systemic treatment (ST), a radical approach with surgery or local therapy (LT) may be treatment options.

Aim(s): Show our experience in management of metastatic ACC (mACC) with LT options after a partial response (PR) a ST.

Materials and methods: Retrospective assessment of progress and clinical and radiological therapy response, comparing it to the guidelines recommendations.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Morales Herrero R, Herrero Rivera D, Santos Fernández P, Benavent M,

Keywords: ACC, chemotherapy, mitotane, local therapy,